Comparison of Long-Term Survival and Toxicity of Cisplatin Delivered Weekly versus Every Three Weeks Concurrently with Intensity-Modulated Radiotherapy in Nasopharyngeal CarcinomaReport as inadecuate




Comparison of Long-Term Survival and Toxicity of Cisplatin Delivered Weekly versus Every Three Weeks Concurrently with Intensity-Modulated Radiotherapy in Nasopharyngeal Carcinoma - Download this document for free, or read online. Document in PDF available to download.

Background

We aimed to compare the long-term survival outcomes and acute toxicity of cisplatin administered weekly versus every three weeks concurrently with intensity-modulated radiotherapy IMRT in patients with nasopharyngeal carcinoma NPC.

Methods

This was a retrospective review of 154 patients with histologically proven, non-disseminated NPC who were treated using IMRT between January 2003 and December 2007. Seventy-three patients 47.4% received 5–7 weeks of 30–40 mg-m2 cisplatin weekly; 81 patients 52.6% received two or three cycles of 80 mg-m2 cisplatin every three weeks. IMRT was delivered at 68 Gy-30 fractions to the nasopharyngeal gross target volume and 60–66 Gy to the involved neck area.

Results

The clinical characteristics and treatment factors of the two groups were well-balanced. The median follow-up was 74 months range, 6–123 months, and the 5-year overall survival, disease-free survival, locoregional relapse-free survival, and distant metastasis–free survival rates were 85.2% vs. 78.9% P = 0.318, 71.6% vs. 71.0% P = 0.847, 93.5% vs. 92.6% P = 0.904, and 80.9% vs. 80.1% P = 0.925 for the group treated every three weeks and weekly, respectively. Subgroup analyses indicated no significant differences in the survival rates of the two groups among patients with early- or advanced-stage disease. The incidence of acute toxicities was similar between groups.

Conclusion

IMRT with concurrent cisplatin administered weekly or every three weeks leads to similar long-term survival outcomes and acute toxicity in NPC regardless of whether patients have early- or advanced-stage disease.



Author: Chang-Juan Tao , Li Lin , Guan-Qun Zhou, Ling-Long Tang, Lei Chen, Yan-Ping Mao, Mu-Sheng Zeng, Tie-Bang Kang, Wei-Hua Jia, Jian-

Source: http://plos.srce.hr/



DOWNLOAD PDF




Related documents